198 related articles for article (PubMed ID: 9708408)
1. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative.
Bartlett JA; Wasserman SS; Hicks CB; Dodge RT; Weinhold KJ; Tacket CO; Ketter N; Wittek AE; Palker TJ; Haynes BF
AIDS; 1998 Jul; 12(11):1291-300. PubMed ID: 9708408
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12.
Sha BE; Onorato M; Bartlett JA; Bosch RJ; Aga E; Nokta M; Adams EM; Li XD; Eldridge J; Pollard RB
AIDS; 2004 May; 18(8):1203-6. PubMed ID: 15166537
[TBL] [Abstract][Full Text] [Related]
3. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
Liao HX; Cianciolo GJ; Staats HF; Scearce RM; Lapple DM; Stauffer SH; Thomasch JR; Pizzo SV; Montefiori DC; Hagen M; Eldridge J; Haynes BF
Vaccine; 2002 May; 20(17-18):2396-403. PubMed ID: 12009296
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
Salmon-Céron D; Excler JL; Finkielsztejn L; Autran B; Gluckman JC; Sicard D; Matthews TJ; Meignier B; Valentin C; El Habib R; Blondeau C; Raux M; Moog C; Tartaglia J; Chong P; Klein M; Milcamps B; Heshmati F; Plotkin S
AIDS Res Hum Retroviruses; 1999 May; 15(7):633-45. PubMed ID: 10331442
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
[TBL] [Abstract][Full Text] [Related]
6. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers.
Rubinstein A; Goldstein H; Pettoello-Mantovani M; Mizrachi Y; Bloom BR; Furer E; Althaus B; Que JU; Hasler T; Cryz SJ
AIDS; 1995 Mar; 9(3):243-51. PubMed ID: 7755912
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
Salmon-Céron D; Excler JL; Sicard D; Blanche P; Finkielstzjen L; Gluckman JC; Autran B; Matthews TJ; Meignier B; Kieny MP
AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1479-86. PubMed ID: 8679292
[TBL] [Abstract][Full Text] [Related]
10. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
[TBL] [Abstract][Full Text] [Related]
11. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
Vogel T; Kurth R; Norley S
J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection.
Kelleher AD; Emery S; Cunningham P; Duncombe C; Carr A; Golding H; Forde S; Hudson J; Roggensack M; Forrest BD; Cooper DA
AIDS Res Hum Retroviruses; 1997 Jan; 13(1):29-32. PubMed ID: 8989424
[TBL] [Abstract][Full Text] [Related]
13. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
Bures R; Gaitan A; Zhu T; Graziosi C; McGrath KM; Tartaglia J; Caudrelier P; El Habib R; Klein M; Lazzarin A; Stablein DM; Deers M; Corey L; Greenberg ML; Schwartz DH; Montefiori DC
AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2019-35. PubMed ID: 11153085
[TBL] [Abstract][Full Text] [Related]
14. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination.
Locher CP; Grant RM; Collisson EA; Reyes-Terán G; Elbeik T; Kahn JO; Levy JA
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1685-9. PubMed ID: 10606091
[TBL] [Abstract][Full Text] [Related]
15. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients.
Pinto LA; Berzofsky JA; Fowke KR; Little RF; Merced-Galindez F; Humphrey R; Ahlers J; Dunlop N; Cohen RB; Steinberg SM; Nara P; Shearer GM; Yarchoan R
AIDS; 1999 Oct; 13(15):2003-12. PubMed ID: 10546852
[TBL] [Abstract][Full Text] [Related]
16. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
Clements-Mann ML; Weinhold K; Matthews TJ; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Hsieh RH; Mestecky J; Zolla-Pazner S; Mascola J; Schwartz D; Siliciano R; Corey L; Wright PF; Belshe R; Dolin R; Jackson S; Xu S; Fast P; Walker MC; Stablein D; Excler JL; Tartaglia J; Paoletti E
J Infect Dis; 1998 May; 177(5):1230-46. PubMed ID: 9593008
[TBL] [Abstract][Full Text] [Related]
17. Studies on V3-specific cross-reactive T-cell responses in chimpanzees chronically infected with HIV-1IIIB.
Nehete PN; Murthy KK; Satterfield WC; Arlinghaus RB; Sastry KJ
AIDS; 1995 Jun; 9(6):567-72. PubMed ID: 7662194
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals.
Seth A; Yasutomi Y; Jacoby H; Callery JC; Kaminsky SM; Koff WC; Nixon DF; Letvin NL
AIDS Res Hum Retroviruses; 2000 Mar; 16(4):337-43. PubMed ID: 10716371
[TBL] [Abstract][Full Text] [Related]
19. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120.
Nehete PN; Casement KS; Arlinghaus RB; Sastry KJ
Cell Immunol; 1995 Feb; 160(2):217-23. PubMed ID: 7720083
[TBL] [Abstract][Full Text] [Related]
20. A region of the third variable loop of HIV-1 gp120 is recognized by HLA-B7-restricted CTLs from two acute seroconversion patients.
Safrit JT; Lee AY; Andrews CA; Koup RA
J Immunol; 1994 Oct; 153(8):3822-30. PubMed ID: 7523505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
